GlassScriptPhysician profile
Erica Thompson
NPI 1073276002
$3,250.37
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,262 · 2023: $1,487 · 2024: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,988.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $625.73 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $314.25 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $300.42 | 2022-2024 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $281.05 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.08 | 2022-2024 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $174.31 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.03 | 2022-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $139.08 | 2022-2024 | |
| Novo Nordisk INC | $136.54 | 2022-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $134.21 | 2022-2024 | |
| Glaxosmithkline, LLC. | $120.46 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Vanda Pharmaceuticals INC. | $90.12 | 2022-2023 | Hetlioz |
| Janssen Pharmaceuticals, INC | $78.10 | 2022-2024 | Xarelto |
| Dexcom, INC. | $69.56 | 2023-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $63.52 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $61.58 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $60.68 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.62 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $52.97 | 2022-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.11 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $28.42 | 2023 | Inpefa |
| Daiichi Sankyo INC. | $26.74 | 2023 | Injectafer |
| Novavax INC | $24.10 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Kowa Pharmaceuticals America, INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.